Monoclonal Antibody Production by Multiple Methods.Get mAb Less Than 70 Days.Free Inquiry. Antibody Production- mAb, pAb Phospho, Hapten.One-Stop Service.Choose Your Need!
- Membrane Protein Antibody
Anti-Membrane Protein Ab Production
Whole Cell Antigen Presentation
- Biomolecules Engineering
Antibody Engineering Services
Antibody Modification Services
- For Enzyme Conjugate
Provide Antibody discovery service
for enzyme conjugate for our ...
- MUC2 mAbs
Stock & Custom MUC2 Anti-Glycan
Monoclonal Antibodies. Fast ...
- ADC Antibody Screening
Advanced antibody screening
platform ensures the first step ...
- ABO Glycan mAbs
ABO Glycan mAbs
Creative Biolabs
- Membrane Protein Antibody
Search results
Nov 30, 2018 · Autoimmune hemolytic anemia (AIHA) is a decompensated acquired hemolysis caused by the host’s immune system acting against its own red cell antigens. Consequent complement activation can impact the clinical picture and is an emerging target for therapeutic approaches.
- Anita Hill, Quentin A. Hill
- 2015
Jun 1, 2017 · Antibodies directed against self-erythrocytes capable of induction of hemolysis at excessive or uncompensated rates result in an entity known as AIHA. These antibodies are usually immunoglobulin G (IgG) in nature, capable of fixing complement, and are detected by the DAT.
- Ronald S. Go, Jeffrey L. Winters, Neil E. Kay
- 2017
Oct 24, 2017 · Antibodies play an essential role in host defence against pathogens by binding to microorganisms and infected cells and exerting various effector functions.
- Lenette L. Lu, Todd J. Suscovich, Sarah M. Fortune, Galit Alter
- 2018
This report on ‘Antibodies to watch in 2017’ includes details of 52 mAbs currently in late-stage studies for cancer (20 mAbs) or non-cancer (32 mAbs) indications, 9 mAbs with first marketing applications under review, and 7 antibodies that were granted first marketing approvals in 2016.
- Janice M. Reichert
- 2017
As of December 1, 2017, nine antibody therapeutics (ibalizumab, burosumab, tildrakizumab, caplacizumab, erenumab, fremanezumab, galcanezumab, romosozumab, mogamulizumab) were in regulatory review in the EU or US, and regulatory actions on their marketing applications are expected by the end of 2018.
- Hélène Kaplon, Janice M Reichert
- 2018
Antibodies, Monoclonal. Antineoplastic Agents. Over 50 investigational monoclonal antibody (mAb) therapeutics are currently undergoing evaluation in late-stage clinical studies, which is expected to drive a trend toward first marketing approvals of at least 6-9 mAbs per year in the near-term.
People also ask
How do antigen-binding fragments and FC domains influence antibody function?
How do antibodies affect quorum sensing and biofilm formation?
How are antibody effector functions regulated?
Does the antibody Fc domain affect the Fab domain?
What role do antibodies play in a host defense against pathogens?
What factors affect antibody-antibody complex quality?
Apr 4, 2018 · Antibody use is a critical component of cardiovascular physiology research, and antibodies are used to monitor protein abundance (immunoblot analysis) and protein expression and localization (in tissue by immunohistochemistry and in cells by immunocytochemistry).
